Cancer Genetics (CGIX) Reports Q3 EPS of $0.98 (Earlier)

Cancer Genetics (NASDAQ: CGIX) reported Q3 EPS of $0.98, versus ($9.34) reported last year. Revenue for the quarter came in at $2.1 million, versus $535 thousand reported last year.

For earnings history and earnings-related data on Cancer Genetics (CGIX) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Newton Golf Company (NWTG) Reports Q2 Loss of $0.49
• Reading (RDI) Tops Q2 EPS by 4c